Compare Stocks: TRVI, SMMT, RDY, and NUVL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
RDY Dr. Reddy's Laboratories	$12.07 +1.9%	$13.32	$11.36 ▼ $15.67	$10.08B	0.25	2.40 million shs	2.53 million shs
SMMT Summit Therapeutics	$13.03 +0.0%	$14.65	$12.25 ▼ $30.98	$10.39B	-1.23	3.98 million shs	2.34 million shs
TRVI Trevi Therapeutics	$17.91 -1.9%	$16.55	$6.55 ▼ $20.22	$2.54B	1	1.73 million shs	832,335 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVL Nuvalent	0.00%	0.00%	+0.19%	+25.16%	+59.41%
RDY Dr. Reddy's Laboratories	0.00%	+0.59%	-17.67%	-13.70%	-15.09%
SMMT Summit Therapeutics	0.00%	-4.69%	-15.56%	-19.18%	-51.90%
TRVI Trevi Therapeutics	0.00%	+4.11%	+1.78%	+31.58%	+148.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVL Nuvalent	$123.96	$118.13	$71.13 ▼ $123.99	$9.79B	1.14	1.93 million shs	N/A
RDY Dr. Reddy's Laboratories	$12.07 +1.9%	$13.32	$11.36 ▼ $15.67	$10.08B	0.25	2.40 million shs	2.53 million shs
SMMT Summit Therapeutics	$13.03 +0.0%	$14.65	$12.25 ▼ $30.98	$10.39B	-1.23	3.98 million shs	2.34 million shs
TRVI Trevi Therapeutics	$17.91 -1.9%	$16.55	$6.55 ▼ $20.22	$2.54B	1	1.73 million shs	832,335 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVL Nuvalent	0.00%	0.00%	+0.19%	+25.16%	+59.41%
RDY Dr. Reddy's Laboratories	0.00%	+0.59%	-17.67%	-13.70%	-15.09%
SMMT Summit Therapeutics	0.00%	-4.69%	-15.56%	-19.18%	-51.90%
TRVI Trevi Therapeutics	0.00%	+4.11%	+1.78%	+31.58%	+148.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NUVL Nuvalent	2.15	Hold	$127.73	3.04% Upside
RDY Dr. Reddy's Laboratories	1.67	Reduce	N/A	N/A
SMMT Summit Therapeutics	2.44	Hold	$26.15	100.80% Upside
TRVI Trevi Therapeutics	3.00	Buy	$24.91	39.06% Upside

Current Analyst Ratings Breakdown

Latest TRVI, SMMT, RDY, and NUVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2026	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
7/24/2026	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $38.00
7/24/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
7/24/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/23/2026	RDY Dr. Reddy's Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/23/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$36.00
7/20/2026	TRVI Trevi Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	TRVI Trevi Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $31.00
7/20/2026	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $24.00
7/17/2026	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NUVL Nuvalent	N/A	N/A	N/A	N/A	$15.95 per share	N/A
RDY Dr. Reddy's Laboratories	$331.19B	0.03	$0.86 per share	13.99	$4.86 per share	2.48
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NUVL Nuvalent	-$425.38M	-$6.06	N/A	N/A	N/A	N/A	-40.11%	-35.43%	8/6/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.43	20.46	2.38	10.15%	9.49%	6.32%	N/A
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)
TRVI Trevi Therapeutics	-$42.76M	-$0.32	N/A	N/A	N/A	N/A	-24.53%	-23.37%	8/6/2026 (Estimated)

Latest TRVI, SMMT, RDY, and NUVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NUVL Nuvalent	-$1.44	N/A	N/A	N/A	$0.25 million	N/A
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	N/A	N/A	N/A	N/A	N/A
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A
5/12/2026	Q4 25/26	RDY Dr. Reddy's Laboratories	$0.09	$0.06	-$0.03	-$0.03	$886.58 million	$852.55 million
5/7/2026	Q1 2026	NUVL Nuvalent	-$1.35	-$1.39	-$0.04	-$1.39	$0.49 million	N/A
5/5/2026	Q1 2026	TRVI Trevi Therapeutics	-$0.07	-$0.09	-$0.02	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.50%	+6.96%	13.64%	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NUVL Nuvalent	N/A	16.14	16.14
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
SMMT Summit Therapeutics	N/A	6.96	6.96
TRVI Trevi Therapeutics	N/A	24.75	24.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NUVL Nuvalent	97.26%
RDY Dr. Reddy's Laboratories	3.85%
SMMT Summit Therapeutics	4.61%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
NUVL Nuvalent	5.02%
RDY Dr. Reddy's Laboratories	2.00%
SMMT Summit Therapeutics	83.50%
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NUVL Nuvalent	40	79.00 million	75.03 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable
TRVI Trevi Therapeutics	20	141.98 million	120.13 million	Optionable

TRVI, SMMT, RDY, and NUVL Headlines

Recent News About These Companies

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts

July 31 at 4:28 AM | marketbeat.com

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Trevi Therapeutics (TRVI) to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

Trevi Therapeutics to Participate in Upcoming August Conferences

July 28, 2026 | globenewswire.com

Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI

July 25, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

July 25, 2026 | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

July 25, 2026 | marketbeat.com

Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI

July 24, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets

July 22, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why

July 20, 2026 | marketbeat.com

B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

July 20, 2026 | marketbeat.com

HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

July 20, 2026 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Here's Why

July 18, 2026 | marketbeat.com

Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market

July 17, 2026 | insidermonkey.com

Trevi climbs after late-stage trial setback for GSK cough therapy

July 17, 2026 | msn.com

Why Trevi Therapeutics, Inc.’s (TRVI) Stock Is Up 10.08%

July 17, 2026 | aaii.comA

Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?

July 17, 2026 | marketbeat.com

Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)

July 15, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI, SMMT, RDY, and NUVL Company Descriptions

Nuvalent NASDAQ:NUVL

$123.96 0.00 (0.00%)

As of 07/16/2026

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Dr. Reddy's Laboratories NYSE:RDY

$12.06 +0.22 (+1.81%)

As of 04:00 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Summit Therapeutics NASDAQ:SMMT

$13.04 +0.02 (+0.19%)

As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Trevi Therapeutics NASDAQ:TRVI

$17.91 -0.34 (-1.85%)

Closing price 03:59 PM Eastern

Extended Trading

$17.90 -0.01 (-0.07%)

As of 04:01 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRVI, SMMT, RDY, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRVI, SMMT, RDY, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRVI, SMMT, RDY, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI, SMMT, RDY, and NUVL Company Descriptions

Nuvalent NASDAQ:NUVL

Dr. Reddy's Laboratories NYSE:RDY

Summit Therapeutics NASDAQ:SMMT

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRVI, SMMT, RDY, and NUVL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRVI, SMMT, RDY, and NUVL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRVI, SMMT, RDY, and NUVL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI, SMMT, RDY, and NUVL Company Descriptions

Nuvalent NASDAQ:NUVL

Dr. Reddy's Laboratories NYSE:RDY

Summit Therapeutics NASDAQ:SMMT

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools